PET imaging of DNA and RNA synthesis
Nucleosides/nucleotides
Cells acquire the deoxyribonucleoside triphosphates, building blocks of DNA, by de novo synthesis (utilised by most cells) and by salvage (utilized by lymphoid organs and rapidly proliferating cells). Glucose and amino acids are the precursors of the de novo pathway, while the salvage pathway relies on nucleoside transporters and cytosolic deoxyribonucleoside kinases. Transporters include the human equilibrative nucleoside transporter-1 (hENT1). Thymidine kinase 1 (TK1) phosphorylates thymidine and deoxyuridine, and deoxycytidine kinase (dCK) phosphorylates deoxycytidine, deoxyadenosine, and deoxyguanosine (Sabini et al., 2008). Deoxyguanosine kinase is a mitochondrial enzyme. Uridine-cytidine kinases phosphorylate uridine and cytidine to uridine and cytidine monophosphates (van Kuilenburg & Meinsma, 2016). Nucleotide analogues have been developed as PET radiotracers for imaging the salvage pathways of DNA synthesis, especially in cancer and T cell imaging.
Thymidine kinase activity can be assessed using its substrates such as [18F]FLT (3'-deoxy-3'-[18F]fluorothymidine), an analogue of thymidine which is phosphorylated by TK1 but not incorporated in DNA (Shields et al., 1998) and used extensively in cancer imaging. Tracers which are incorporated in DNA include [18F]FMAU ( Sun et al., 2005; Tehrani et al., 2007) and [11C]4DST (Takami et al., 2018; Fukuda et al., 2019).
Deoxycytidine kinase activity can be measured with substrates such as [18F]CFA ([18F]clofarabine, 2-chloro-9-(2′-deoxy-2′-[18F]fluoro β-d-arabinofuranosyl)adenine) (Kim et al., 2016; Barrio et al., 2017).
Uridine-cytidine kinase 1 (UCK1) is expressed in most tissues, while uridine-cytidine kinase 2 (UCK2) is expressed mainly in placenta and several types of cancer. Therefore, UCK2 has been targeted in antitumour drug development. UCK2-selective uridine analogues EUrd and IV-14 form triphosphates that inhibit RNA polymerases; IV-14 has been labelled with 124I (Cao et al., 2025).
PCNA
Proliferating cell nuclear antigen (PCNA) participates in DNA replication and repair, and is upregulated in proliferating cells. In clinical trials, PCNA inhibitors have reduced tumour growth (Wang & Wang, 2025). PET tracers targeting PCNA are in development, including [18F]FPON (Zheng et al., 2026).
See also:
- [18F]Fluorothymidine
- PET imaging of cancer
- PARP and PARPi PET imaging
- Oligonucleotides in PET imaging
- Histone deacetylases (HDACs)
Literature
Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta 1996; 1286(3): 153-181. doi: 10.1016/s0304-4157(96)00008-1.
King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol. Sci. 2006; 27(8): 416-425. doi: 10.1016/j.tips.2006.06.004.
Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2005; 43(1): 153-167. doi: 10.1016/j.rcl.2004.09.005.
Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013; 54(6): 903-912. doi: 10.2967/jnumed.112.112201.
Tags: DNA, Cell proliferation, Tumour
Updated at: 2026-11-11
Created at: 2026-11-10
Written by: Vesa Oikonen